Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
S-phase cancer associated transcript 1 (SCAT1) is a long non-coding RNA (lncRNA) encoded by the human genome and expressed primarily during the S-phase of the cell cycle. It is differentially expressed in various tumor types and acts as an independent prognostic biomarker, notably in lung and kidney cancers. SCAT1 participates in the regulation of crucial cancer cell hallmarks including cell proliferation, cell cycle progression, and apoptosis. Experimental depletion of SCAT1 in cancer cell models impairs cell proliferation, causes cell cycle arrest, and induces apoptosis, indicating its functional importance in oncogenesis. SCAT1 is part of a larger family of S-phase-enriched lncRNAs implicated in tumor progression and patient prognosis[1][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on S-phase cancer associated transcript 1 (SCAT1).